Operator
Good afternoon and welcome to the Avacta Group PLC Investor Presentation. [Operator Instructions] And then I’d like to hand you over to the management team. Christina, good afternoon.
Christina Coughlin
CEO & Executive Director
Good afternoon. Thank you very much coming to you from London, and a very good morning to our colleagues joining from the United States. We’re thrilled today to bring you our fiscal year 2025 preliminary results and a short business update.
Let me start first on the research and development side for our company. The Avacta vision and our strategy, our vision is to conquer cancer with existing therapies while preserving patient vitality and improve healing.
You’ve heard us say that in a world where effective cancer therapy often means a difficult trade-off between efficacy and safety, our pre|CISION platform has the potential to offer something very different, hope without compromise. The strategy for Avacta is to develop and ultimately to commercialize a broad portfolio of drugs, given that importantly, FAP or the enzyme that our platform is based on is expressed in 90% of solid tumors, which represents a very large market opportunity for our pre|CISION technology.
Our technology is capable of repurposing a range of oncology drugs to significantly reduce toxicity by concentrating the drug directly in the tumor. With these, we are challenging the current drug delivery methods, and our goal is to expand the reach of many of the highly potent anticancer therapies that we have seen in the field of oncology.
Let me turn to our fiscal year 2025 highlights. First, on the research and development on the R&D side. Over the
